Literature DB >> 16437456

Antidepressants for depressed elderly.

P Mottram1, K Wilson, J Strobl.   

Abstract

BACKGROUND: Depression is a relatively common experience in older adults. The syndrome is associated with considerable distress, morbidity and service commitment. Approximately two thirds of patients presenting with severe forms will respond to antidepressant treatment and the last twenty years has witnessed a great increase in the number of these drugs. Older, frail people are particularly vulnerable to side effects.
OBJECTIVES: The aims of this review were to examine the efficacy of antidepressant classes, to compare the withdrawal rates associated with each class and describe the side effect profile of antidepressant drugs for treating depression in patients described as elderly, geriatric, senile or older adults, aged 55 or over. SEARCH STRATEGY: The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR-Studies) was searched (2003-08-13). Reference lists of relevant papers and previous systematic reviews were hand searched for published reports and citations of unpublished studies. SELECTION CRITERIA: Only randomised controlled trials were included. Trials had to compare at least two active antidepressant drugs in the treatment of depression. DATA COLLECTION AND ANALYSIS: Reviewers extracted data independently. In examining efficacy, the reviewers assumed that people who died or dropped out had no improvement. Withdrawal rates irrespective of cause and specifically due to side effects were compared between drug classes. Relative risk (RR) for dichotomous data and weighted mean difference for continuous data were calculated with 95% confidence intervals (CI). Qualitative side effect data were reported in terms of ratios of side effects and percentage of patients experiencing specific side effects. MAIN
RESULTS: A total of 29 trials provided data for inclusion in the review. We were unable to find any differences in efficacy when comparing classes of antidepressants. However, as the trials contained relatively small numbers of patients, these findings may be explained by a type two error. Tricyclic antidepressants (TCAs) compared less favourably with selective serotonin reuptake inhibitors (SSRIs) in terms of numbers of patients withdrawn irrespective of reason (RR: 1.24, CI 1.04, 1.47) and number withdrawn due to side effects (RR: 1.30, CI 1.02, 1.64). Subgroup analyses demonstrated that TCA related antidepressants had similar withdrawal rates to SSRIs irrespective of reason of withdrawal (RR: 1.49, CI 0.74, 2.98) or withdrawal due to side effects (RR: 1.07, CI 0.43, 2.70). The qualitative analysis of side effects showed a small increased profile of gastro-intestinal and neuropsychiatric side effects associated with classical TCAs. AUTHORS'
CONCLUSIONS: Our findings suggest that SSRIs and TCAs are of the same efficacy. However, we have found some evidence suggesting that TCA related antidepressants and classical TCAs may have different side effect profiles and are associated with differing withdrawal rates when compared with SSRIs. The review suggests that classical TCAs are associated with a higher withdrawal rate due to side effect experience, although these results must be interpreted with caution due to the relatively small size of the review and the heterogeneity of the drugs and patient populations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16437456     DOI: 10.1002/14651858.CD003491.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  52 in total

1.  Serotonin-norepinephrine reuptake inhibitor antidepressants and the risk of falls in older people: case-control and case-series analysis of a large UK primary care database.

Authors:  Jonathan Gribbin; Richard Hubbard; John Gladman; Chris Smith; Sarah Lewis
Journal:  Drugs Aging       Date:  2011-11-01       Impact factor: 3.923

Review 2.  Depression and frailty in later life: a synthetic review.

Authors:  Briana Mezuk; Lauren Edwards; Matt Lohman; Moon Choi; Kate Lapane
Journal:  Int J Geriatr Psychiatry       Date:  2011-10-07       Impact factor: 3.485

Review 3.  Invited article: improving safety for the neurologic patient: evaluating medications, literacy, and abuse.

Authors:  A Depold Hohler; J Doyle Lee; E A Schulman; J A Schafer; C Flippen
Journal:  Neurology       Date:  2010-08-24       Impact factor: 9.910

Review 4.  The clinical implications of ageing for rational drug therapy.

Authors:  Shaojun Shi; Klaus Mörike; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-01-05       Impact factor: 2.953

Review 5.  Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly.

Authors:  Brian Draper; Karen Berman
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 6.  A review of the effectiveness of antidepressant medications for depressed nursing home residents.

Authors:  Richard D Boyce; Joseph T Hanlon; Jordan F Karp; John Kloke; Ahlam Saleh; Steven M Handler
Journal:  J Am Med Dir Assoc       Date:  2011-10-21       Impact factor: 4.669

Review 7.  Use of antidepressants in late-life depression.

Authors:  Tarek K Rajji; Benoit H Mulsant; Francis E Lotrich; Cynthia Lokker; Charles F Reynolds
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

8.  [Improvement of knowledge and attitudes towards depression and suicidality in geriatric caregivers: evaluation of an advanced training program].

Authors:  Antje-Kathrin Allgaier; Dietmar Kramer; Roland Mergl; Ulrich Hegerl
Journal:  Z Gerontol Geriatr       Date:  2009-06-28       Impact factor: 1.281

9.  [Pharmacotherapy of depression in the elderly].

Authors:  V Holthoff
Journal:  Z Gerontol Geriatr       Date:  2013-02       Impact factor: 1.281

10.  Guidelines abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adults with Diabetes Mellitus: 2013 update.

Authors:  Gerardo Moreno; Carol M Mangione; Lindsay Kimbro; Ekaterina Vaisberg
Journal:  J Am Geriatr Soc       Date:  2013-11       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.